Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 3, 2009
CompletedFirst Posted
Study publicly available on registry
December 4, 2009
CompletedDecember 4, 2009
December 1, 2009
December 3, 2009
December 3, 2009
Conditions
Study Arms (3)
7 days
ACTIVE COMPARATOR20 days
ACTIVE COMPARATORsham
SHAM COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- vitreous haemorrhage
- tractional retinal detachment
- active proliferative diabetic retinopathy.
You may not qualify if:
- neovascular glaucoma
- cataract
- combined traction and rhegmatogenous RD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Campania Luigi Vanvitellilead
- Napoli CTO Hospitalcollaborator
Related Publications (1)
di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. doi: 10.1007/s00417-010-1303-3. Epub 2010 Feb 5.
PMID: 20135139DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Purpose
- TREATMENT
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 3, 2009
First Posted
December 4, 2009
Last Updated
December 4, 2009
Record last verified: 2009-12